~(131)I治疗Graves病后甲状腺缩小程度及相关因素分析

目的:对131I治疗Graves甲亢患者甲状腺体积缩小程度及相关因素进行综合性分析。方法:对首次接受131I治疗的190例Graves甲亢患者,随访观察3个月,详细记录其治疗前后3个月临床及相关检查资料。采用χ2检验、方差分析及多因素回归分析等方法对其进行统计学分析。结果:(1)单因素统计学分析结果显示:甲状腺最高吸131I率(P=0.033)、131I治疗前甲状腺重量、服用131I剂量及患者服用抗甲状腺药物情况、血清甲状腺激素水平等因素与131I治疗后甲状腺体积缩小程度有关(P<0.05)。(2)多因素统计学分析结果显示:未服抗甲状腺药的患者比服用药物的患者、血清甲状腺激素水平高于正常3倍者较其余血清甲状腺激素水平患者的甲状腺体积缩小较为明显。结论:131I治疗后甲状腺体积缩小程度与患者服用抗甲状腺药物情况、血清甲状腺激素水平以及甲状腺最高吸131I率、131I治疗前甲状腺重量以及服用131I剂量等因素有关。

The relative analysis about the volumetric reduction degree of thyroid for the patient with Graves disease who were therapied by ~(131)I

Objective: To analyse the volumetric reduction degree of thyroid for the patients with Graves disease who were therapied by 131I. Methods: 190 patients with Graves disease who firstly accepted the 131I therapy were detailedly recorded their clinical and relative data before and after the 131I therapy. The several statistical methods, such as analysis of variance, chi-square test, cumulative logistic model, etc, were applied to data's analysis. Results: (1)The results of un-variable analysis showed that the highest absorption of 131I(P=0.033) , the weight of thyroid before 131I therapy, the treatment dosage of 131I, the condition of the patients taking anti-thyroid drugs and the level of thyroid hormone in the serum were correlated to the volumetric reduction degree of thyroid(P<0.05). (2)The result of multivariate analysis showed that the volumetric reduction of thyroid of the patients un-taking anti-thyroid drug were better than the patient taking anti-thyroid drug;the patients whose level of thyroid hormone in the serum was three times than the normal were better than the others. Conclusion: The volumetric reduction degree of thyroid after the 131I therapy is influenced by many factors,such as the condition of the patients taking anti-thyroid drugs, the level of thyroid hormone in the serum and the highest absorption of 131I,the weight of thyroid before 131I therapy, the treatment dosage of 131I and so on.